StockNews.com Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Strong-Buy

StockNews.com upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a buy rating to a strong-buy rating in a research note released on Friday morning.

Several other equities research analysts also recently commented on REGN. Morgan Stanley increased their price objective on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an overweight rating in a report on Wednesday, March 13th. Barclays boosted their price objective on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an overweight rating in a research note on Tuesday, January 23rd. BMO Capital Markets raised their target price on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an outperform rating in a research note on Monday, February 5th. Royal Bank of Canada reissued an outperform rating and set a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. Finally, Sanford C. Bernstein began coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They set an outperform rating and a $1,125.00 target price for the company. One research analyst has rated the stock with a sell rating, four have issued a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of Moderate Buy and an average target price of $970.57.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $898.56 on Friday. Regeneron Pharmaceuticals has a 12 month low of $684.80 and a 12 month high of $998.33. The company’s fifty day simple moving average is $956.81 and its 200-day simple moving average is $889.95. The firm has a market cap of $98.63 billion, a PE ratio of 25.86, a P/E/G ratio of 2.64 and a beta of 0.11. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. During the same period in the prior year, the business posted $10.96 EPS. The company’s quarterly revenue was up .6% on a year-over-year basis. Equities research analysts expect that Regeneron Pharmaceuticals will post 38.18 EPS for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Joseph L. Goldstein sold 2,707 shares of the business’s stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $950.00, for a total transaction of $2,571,650.00. Following the completion of the transaction, the director now owns 6,382 shares of the company’s stock, valued at approximately $6,062,900. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the transaction, the executive vice president now directly owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Joseph L. Goldstein sold 2,707 shares of the stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $950.00, for a total transaction of $2,571,650.00. Following the completion of the transaction, the director now directly owns 6,382 shares of the company’s stock, valued at approximately $6,062,900. The disclosure for this sale can be found here. In the last quarter, insiders have sold 13,729 shares of company stock valued at $13,124,641. 8.83% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. FMR LLC raised its position in Regeneron Pharmaceuticals by 7.3% in the third quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock valued at $8,098,661,000 after purchasing an additional 669,517 shares during the last quarter. Vanguard Group Inc. raised its holdings in Regeneron Pharmaceuticals by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 8,838,285 shares of the biopharmaceutical company’s stock valued at $7,762,577,000 after buying an additional 39,780 shares during the last quarter. Capital World Investors boosted its position in Regeneron Pharmaceuticals by 0.5% during the 4th quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock worth $4,506,071,000 after buying an additional 23,146 shares during the period. Putnam Investments LLC grew its holdings in Regeneron Pharmaceuticals by 2.1% during the 4th quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock worth $1,063,377,000 after acquiring an additional 24,329 shares during the last quarter. Finally, Northern Trust Corp increased its position in Regeneron Pharmaceuticals by 3.3% in the 3rd quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company’s stock valued at $878,271,000 after acquiring an additional 34,326 shares during the period. 83.31% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.